Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime

Imran, Muhammad; Shah, Muhammad Raza; Ullah, Farhat; Ullah, Shafi; Elhissi, Abdelbary; Nawaz, Waqas; Ahmad, Farid; Sadiq, Abdul; Ali, İrshad

doi:10.1016/j.ijpharm.2016.03.042

Cited by 69 publications

(30 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, it showed 80.44 ± 1.83 and 79.77 ± 2.11% cell viability against HeLa cells after 24 and 48 h, respectively, at 1000 mg/mL. The minimal cytotoxicity of the novel sugar-based surfactant can be attributed to its nonionic nature and saturation in its structure (Imran et al, 2016). The appropriate alkyl chain length of the surfactant might be responsible for the lower cytotoxicty of the surfactant as long chains of the amphiphile can have higher disruptive effect on cell membranes (Tao & Uhrich, 2006).…”

Section: In Vitro Cytotoxicitymentioning

confidence: 90%

“…Being with a safe pharmacological profile and reactive multiple sides in its structure, it offers good possibilities for the derivatization of sugar-based nonionic surfactants. We have recently shown that this type of surfactant is applicable for manufacturing niosomal delivery systems of the hydrophobic cephalosporin drugs cefixime, with the ability to increase its solubility and bioavailability using an animal model (Imran et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin

et al. 2016

Self Cite

View full text Add to dashboard Cite

Context: Vesicular systems have attracted great attention in drug delivery because of their amphiphilicity, biodegradability, non-toxicity and potential for increasing drug bioavailability. Objective: A novel sugar-based double-tailed surfactant containing renewable block was synthesized for preparing niosomal vesicles that could be exploited for Levofloxacin encapsulation, aiming to increase its oral bioavailability. Materials and methods: The surfactant was characterized by 1 H NMR, mass spectroscopy and Fourier transform infrared spectroscopy (FT-IR). Its biocompatibility was studied against cell cultures and human blood hemolysis. In vivo acute toxicity was evaluated in mice. The vesicle morphology, size, drug-excipients interaction and entrapment efficiency (EE) were examined using atomic force microscope (AFM), dynamic light scattering (DLS), FT-IR and HPLC. Oral bioavailability studies of Levofloxacin in surfactant-based niosomal formulation were carried out using rabbits and plasma samples were analyzed using HPLC. Results and discussion: Vesicles were spherical in shape and the size was 190.31 ± 4.51 nm with a polydispersity index (PDI) of 0.29 ± 0.03. The drug EE in niosomes was 68.28 ± 3.45%. When applied on cell lines, high cell viability was observed even after prolonged exposure at high concentrations. It caused 5.77 ± 1.34% hemolysis at 1000 mg/mL and was found to be safe up to 2000 mg/kg. Elevated Levofloxacin plasma concentration was achieved when delivered with novel vesicles. Conclusion:The surfactant was demonstrated to be safe and effective as carrier of Levofloxacin. The study suggests that this sugar-based double-tailed nonionic surfactant could be promising nano-vesicular system for delivery and enhancing oral bioavailability of the hydrophobic Levofloxacin.

show abstract

Section: In Vitro Cytotoxicitymentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…3T3 and HeLa cells are well-known cell lines that are mostly used to assess the cytotoxicity of chemical compounds and preferred due to good reproducibility of results (Imran et al, 2016;Vlachy at al., 2009). Cytotoxicity of LC-CRT against mouse embryonic fibroblast NIH/3T3 and human cervical cancer HeLa cell lines was evaluated using MTT.…”

Section: In-vitro Cell Cytotoxictymentioning

confidence: 99%

Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nanotechnology-based drug-delivery systems encapsulating increased amounts of drugs are preferred as they ensure the release of the loaded drugs in a controlled manner. Moreover, nanosystems that load increased amounts of drugs are capable of localizing the increased amount of the drugs in sites of disease , Ullah, Shah et al 2016. The AZ-14-based, AZ-16-based, and AZ-18-based niosomal vesicles encapsulated increased amounts of drug as shown in Table 1.…”

Section: Entrapment Efficiencymentioning

confidence: 99%

“…They form nanostructures with diverse morphologies through their self‐assembly in contact with aqueous medium. Their self‐assembling in aqueous medium results in the formation of a closed bilayer structure known as “niosome.” Nonionic surfactant‐based niosomes are capable of dissolving both hydrophilic and lipophilic molecules within the aqueous spaces and lipid bilayers, respectively (Ahmad and Yasin, ; Imran et al, ). Niosomes have been the subject of immense importance in the field of nanotechnology and drug delivery.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of Triazole‐Based Nonionic Surfactants for Nanostructured Drug Delivery: Investigation of Their Physicochemical and Biological Aspects

Alam

Khan

Ateeq

2019

J Surfact & Detergents

View full text Add to dashboard Cite

Synthesis of novel nonionic surfactants has attracted attention of synthetic chemists due to the issues of the currently used commercial surfactants. The synthesis of three biocompatible triazole‐based nonionic surfactants is reported for nanovesicular drug loading. The surfactants were synthesized in a three‐step reaction and characterized using 1HNMR and mass spectroscopy techniques. They were investigated for their critical micelle concentration (CMC) using a UV–Visible spectrophotometer. Their biocompatibility was investigated against cell culture and in blood. All the synthesized nonionic surfactants were further explored for their nanovesicular drug loading using clarithromycin as a model hydrophobic drug. Nonionic surfactants revealed lower CMC in 35–45 μM and were less hemolytic and cytotoxic. They were capable of self‐assembling in nanosize niosomal vesicles encapsulating increased amounts of drug. The results suggest the synthesized nonionic surfactants as biocompatible nanotechnology‐based drug‐delivery vehicles.

show abstract

Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime

Cited by 69 publications

References 40 publications

Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin

Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin

Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin

Synthesis of Triazole‐Based Nonionic Surfactants for Nanostructured Drug Delivery: Investigation of Their Physicochemical and Biological Aspects

Contact Info

Product

Resources

About